Results 151 to 160 of about 2,148,141 (263)
Comment on: "Adverse Oral Mucosal Reaction to Sublingual Captopril: A Case Report With Exploratory Insights Into AI-Assisted Clinical Reasoning". [PDF]
Spec Care DentistFranco JB.
europepmc +1 more source
The American Journal on Addictions, Volume 35, Issue 6, Page 702-726, November 2026.Abstract Background and Objectives Managing substance use disorders (SUDs) is limited by the lack of longitudinal clinical data during active use and recovery. Wearable devices may help address this gap by capturing physiological and behavioral data in real‐world settings.
Alexandra Sas +10 more
wiley +1 more source
Buccal and sublingual lyophilised naloxone for opioid overdose reversal: A Phase 1 open-label, random-sequence crossover pharmacokinetic study protocol in healthy volunteers (NalBuc). [PDF]
PLoS OneGonzalez Utrilla M +5 more
europepmc +1 more source
Allergy, Volume 81, Issue 11, Page 3920-3935, November 2026.High‐dose birch‐extract nasal challenge induced synchronous peaks at 4 weeks in serum specific IgE (sIgE) and basophil sensitivity. Mast cell sensitivity via tSPT and sIgG1 and sIgG4 responses peaked later, at 6–8 weeks. Preseasonal allergen exposure attenuated seasonal sIgE increase and prevented further rise in tSPT sensitivity.
N. J. Campion +18 more
wiley +1 more source
Permeability Is the Key in Sublingual and Buccal Drug Delivery. [PDF]
PharmaceuticsAlfawaz RMO, Almoazen H.
europepmc +1 more source
Allergy, Volume 81, Issue 11, Page 4039-4050, November 2026.HDM‐pSLIT induced IgG, IgG1, and IgG4 specific to major HDM allergens in sensitized non‐allergic preschool children without increasing HDM‐sIgE. It blunted the development of new sensitizations and reduced HDM reactivity in skin and basophils. HDM‐pSLIT treated children displayed a blocking effect on HDM‐induced basophil activation.
Varsha Dwivedi +12 more
wiley +1 more source
Allergy, Volume 81, Issue 11, Page 4051-4064, November 2026.This is the first randomised placebo‐controlled trial of intralymphatic immunotherapy using a microcrystalline tyrosine‐adjuvanted grass pollen allergoid. Three ultrasound‐guided ILIT injections were well tolerated and reduced combined symptom‐medication scores compared with placebo. The findings support further optimisation and clinical development of
Lara Šošić +13 more
wiley +1 more source
Allergy, Volume 81, Issue 11, Page 3813-3824, November 2026.ABSTRACT Allergen immunotherapy (AIT) has been acknowledged as the only disease‐modifying treatment for respiratory diseases since its introduction in 1911. Although the efficacy and safety have convincingly been established in numerous randomized clinical trials (RCTs), the AIT study results may vary substantially.
Roy Gerth van Wijk +10 more
wiley +1 more source
Atropine-Induced Anticholinergic Syndrome Following Off-Label Sublingual Administration for Refractory Sialorrhea: A Case Report. [PDF]
CureusReboredo P +4 more
europepmc +1 more source
Pre‐Seasonal Treatment With Recombinant Carrier‐Based Birch Vaccine Improves Birch Pollen Allergy
Allergy, Volume 81, Issue 11, Page 3985-4004, November 2026.We conducted a two stage SCIT trial with GNR‐127 containing a recombinant fusion protein consisting of Bet v 1 and Mal d 1‐derived peptides fused to PreS from HBV. Stage 1 identified two safe maximum tolerated doses (40 μg and 80 μg). In the following Stage 2, five preseasonal injections were well tolerated, induced dose‐dependent allergen‐specific IgG,
Musa R. Khaitov +43 more
wiley +1 more source